Associated Papers
Discriminating activating, deactivating and resistance variants in protein kinases.
Singh G et al.
Genome Medicine, 2025
41152984 (PubMed )
Supplement: 13073_2025_1564_MOESM2_ESM.xlsx › Table_S6
Non-canonical CDK6 activity promotes cilia disassembly by suppressing axoneme polyglutamylation.
He K et al.
The Journal of Cell Biology, 2025
CDK6 inhibits de novo lipogenesis in white adipose tissues but not in the liver.
Hu AJ et al.
Nature Communications, 2024
A kinase-independent function of cyclin-dependent kinase 6 promotes outer radial glia expansion and neocortical folding.
Wang L et al.
Proceedings of the National Academy of Sciences of the United States of America, 2022
INK4 Tumor Suppressor Proteins Mediate Resistance to CDK4/6 Kinase Inhibitors.
Li Q et al.
Cancer Discovery, 2022
Defining the landscape of ATP-competitive inhibitor resistance residues in protein kinases.
Persky NS et al.
Nature Structural & Molecular Biology, 2020
MicroRNA-Mediated Suppression of the TGF-β Pathway Confers Transmissible and Reversible CDK4/6 Inhibitor Resistance.
Cornell L et al.
Cell Reports, 2019
CDK6 Antagonizes p53-Induced Responses during Tumorigenesis.
Bellutti F et al.
Cancer Discovery, 2018
CDK6 inhibits white to beige fat transition by suppressing RUNX1.
Hou X et al.
Nature Communications, 2018
Cdk6 contributes to cytoskeletal stability in erythroid cells.
Uras IZ et al.
Haematologica, 2017
CDK6 kinase activity is required for thymocyte development.
Hu MG et al.
Blood, 2011
Negative regulation of TSC1-TSC2 by mammalian D-type cyclins.
Zacharek SJ et al.
Cancer Research, 2005
Cyclin E2, a novel human G1 cyclin and activating partner of CDK2 and CDK3, is induced by viral oncoproteins.
Zariwala M et al.
Oncogene, 1998
Select a paper to view details